RSV Roundtable: Nirsevimab's impact
In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.
EP: 1.RSV Roundtable: What clinicians are witnessing in terms of RSV incidence
EP: 2.RSV Roundtable: Disease education, vaccine hesitancy, and awareness
EP: 3.RSV Roundtable: Nirsevimab's impact
EP: 4.RSV Roundtable: Addressing the senior population
EP: 5.The clinical takeaways of the RSV immunizations
EP: 6.RSV this year: Clinician insights and urgent vaccination strategies
Welcome to the third episode of our 5-episode series; respiratory syncytial virus (RSV) Roundtable, a collaborative project from Contemporary Pediatrics, Contagion, and Contemporary OB/GYN.
This series discusses several aspects of RSV including incidence rates, vaccines, and immunizations.
In this episode, our panel highlights what type of impact nirsevimab (Beyfortus; Sanofi, AstraZeneca) has made this RSV season. In this discussion, the monoclonal antibody's availability and rollout process is also in the spotlight amid a plan to roll out some 230,000 additional doses in January 2024.
Our panel of clinicians includes:
- Robert H. Hopkins Jr., MD: medical director, National Foundation for Infectious Diseases; professor of Internal Medicine and Pediatrics; chief, Division of General Internal Medicine, University of Arkansas for Medical Sciences
- William Muller, MD, PhD: attending physician, Infectious Diseases; Ted Emerson Miller research scholar; professor of Pediatrics (Infectious Diseases), Northwestern University Feinberg School of Medicine; scientific director, Clinical and Community Trials, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children’s Hospital
- Sallie Permar, MD, PhD: Nancy C. Paduano professor and chair, Department of Pediatrics, Weill Cornell Medicine; pediatrician-in-chief, New York-Presbyterian/Weill Cornell Medical Center
- Laura Riley, MD: chair, Department of Obstetrics and Gynecology, Weill Cornell Medicine; obstetrician and gynecologist-in-chief, New York-Presbyterian/Weill Cornell Medical Center
- Neil Silverman, MD: professor, obstetrics and gynecology, David Geffen School of Medicine, UCLA; director, Maternal-Fetal Medicine Fellowship Program
Click here for the first episode of RSV Roundtable.
Click here for the second episode of RSV Roundtable.
This series will release a new episode every Friday through January 5, 2024.
For a full list of already-published episodes, click here.
Thanks for watching RSV Roundtable.
The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants
April 2nd 2022Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.
